معرفی
Helene Lindholm is an Assistant Professor in Biosciences at the University of Skövde, Sweden, affiliated with the School of Bioscience and Department of Biosciences. Her research focuses on cancer biology, particularly pancreatic cancer, with expertise in molecular mechanisms, ROS production, and drug repurposing studies. She maintains an active research program with projects extending through 2025 and teaches bioscience courses at the preparatory level.
Dr. Lindholm's research interests center on pancreatic ductal adenocarcinoma (PDAC), with a particular focus on the repurposing of digitoxin as a potential therapeutic agent. Her work examines how digitoxin affects metabolism, ROS production, and proliferation in pancreatic cancer cells, with special attention to cell phenotypes and biomarkers that predict treatment response. She also investigates the NLRP3 inflammasome pathway and its role in cancer progression, as well as exploring connections between social context, oxytocin, and neural responses. Her research spans molecular biology, cancer metabolism, and pharmacology, bridging fundamental science with potential clinical applications.
Analysis of Dr. Lindholm's publication history reveals a clear research trajectory focused on pancreatic cancer mechanisms and treatment. Her recent work (2022-2024) centers on digitoxin's effects on pancreatic cancer cells, Na+/K+‑ATPase expression, and NLRP3 inflammasome functionality, demonstrating increasing specialization in molecular cancer therapeutics. Earlier publications show broader interests in genetic risk factors for anxiety and chromosomal aberrations in cancer models, reflecting an evolving research focus toward pancreatic cancer therapeutics.
Dr. Lindholm leads two major ongoing research initiatives: 'Evaluation of new pharmaceutical compounds and their effects in the area of cancer and also in stroke' (January 2016-December 2025), which investigates enzymatic inhibitors that reduce ROS production with potential applications in both stroke treatment and cancer therapy; and 'Food–Gut–Brain–Mind–Health' (September 2020-December 2025), a human study examining the whole-body effects of ketogenic diets. Previously, she completed a project on 'NOX, ROS and metabolism in pancreatic cancer' (September 2016-September 2021).
Her research is conducted through the Digital HEAlth Research (DHEAR) initiative at the University of Skövde, where she collaborates with researchers including Katarina Ejeskär, Ferenc Szekeres, Linda Handlin, and India Morrison. Dr. Lindholm's laboratory focuses on understanding the molecular mechanisms of cancer progression and identifying novel therapeutic approaches, employing advanced molecular biology techniques to study cancer cell behavior and drug responses.
